Chlorpheniramine poisoning as a potential cause of rhabdomyolysis.


Journal

The American journal of emergency medicine
ISSN: 1532-8171
Titre abrégé: Am J Emerg Med
Pays: United States
ID NLM: 8309942

Informations de publication

Date de publication:
07 2022
Historique:
received: 13 02 2022
revised: 21 03 2022
accepted: 07 04 2022
pubmed: 24 4 2022
medline: 7 6 2022
entrez: 23 4 2022
Statut: ppublish

Résumé

Chlorpheniramine is an H1 receptor antagonist of the alkylamine class. It is a widely used anti-allergy drug due to its strong antihistamine effect and mild adverse effects. In the case of chlorpheniramine overdose or poisoning, the primary manifestation is central nervous system symptoms. To date, no case of rhabdomyolysis induced by acute poisoning with chlorpheniramine has ever been reported. This study reports a case of acute chlorpheniramine poisoning at an oral dose of 4000 mg, which is the highest reported poisoning dose to date. The diagnosis of rhabdomyolysis (creatine kinase, 195,489 U/L) and acute kidney injury (serum creatinine, 150.1 umol/L) was confirmed based on laboratory results. After haemoperfusion and continuous renal replacement therapy, the patient's renal function fully recovered. This paper aims to analyse the clinical data of this patient and summarize its clinical characteristics. At the same time, the mechanism of chlorpheniramine-induced rhabdomyolysis is also explored in the context of the literature review.

Identifiants

pubmed: 35459564
pii: S0735-6757(22)00242-X
doi: 10.1016/j.ajem.2022.04.010
pii:
doi:

Substances chimiques

Histamine H1 Antagonists 0
Chlorpheniramine 3U6IO1965U
Creatinine AYI8EX34EU
Creatine Kinase EC 2.7.3.2

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

236.e1-236.e3

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All authors have read and approved the submitted manuscript, the manuscript has not been submitted elsewhere nor published elsewhere in whole or in part. Additionally, all authors have approved and contributed to the contents of this paper and have agreed to The American Journal of Emergency Medicine submission policies. The named authors have no conflict of interest, financial or otherwise.

Auteurs

Qingqing Guo (Q)

Department of Intensive Medicine, The First Affiliated Hospital of Fujian Medical University, No.20, Chazhong Road, Taijiang District, Fuzhou, Fujian 350005, China; The First School of Clinical Medicine, Fujian Medical University, No.20, Chazhong Road, Taijiang District, Fuzhou, Fujian 350005, China.

Hao Lin (H)

Shengli Clinical Medical College, Fujian Medical University, No.134, East Street, Gulou District, Fuzhou 350000, Fujian, China; Department of Gastroenterology, Fujian Provincial Hospital South Branch, No. 516, South Jinrong Road, Cangshan District, Fuzhou 350000, Fujian, China.

Jiandong Lin (J)

Department of Intensive Medicine, The First Affiliated Hospital of Fujian Medical University, No.20, Chazhong Road, Taijiang District, Fuzhou, Fujian 350005, China; The First School of Clinical Medicine, Fujian Medical University, No.20, Chazhong Road, Taijiang District, Fuzhou, Fujian 350005, China. Electronic address: Linjd@tom.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH